Wanbury Ltd (WANBURY) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524212 | NSE: WANBURY | Pharmaceuticals & Drugs | Small Cap

Wanbury Share Price

238.05 -6.55 -2.68%
as on 05-Dec'25 16:59

Wanbury Ltd (WANBURY) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524212 | NSE: WANBURY | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Wanbury

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Wanbury stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
17.02
Market Cap:
853.5 Cr.
52-wk low:
155
52-wk high:
330

Is Wanbury Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Wanbury: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Wanbury Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 13.2%59.5%-1.5%26.9%204.9%28.2%206.3%17.7%61.8%36%-
Value Creation
Index
NA3.3NANA13.6NA13.7NA3.41.6-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 423434371391367393511500578600629
Sales YoY Gr.-2.5%-14.5%5.5%-6.1%6.8%30.2%-2.3%15.6%3.8%-
Adj EPS -3.324.9-13.9-10.42.5-4.811-2.99.29.214.4
YoY Gr.-NA-155.7%NANA-293.9%NA-126.5%NA0.1%-
BVPS (₹) -99.3-54.9-67.2-77.5-47.2-52.40.3-2.86.415.730.7
Adj Net
Profit
-6.657.8-32.9-24.66.2-11.935.8-9.530.230.250
Cash Flow from Ops. 43.243.432.529.744.116.740.519.84.726.1-
Debt/CF from Ops. 8.76.26.87.83.79.61.73.223.36.6-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 3.9%10.3%5.5%3.8%
Adj EPS NA30.3%-5.6%0.1%
BVPSNANA278.2%143.6%
Share Price 13.9% 45.5% 69.5% -11.7%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
4-39.82314.4-4.19.6-55.7374.1292.169.461.9
Op. Profit
Mgn %
7.94.3-18.23.6-5.94.36.44.812.511.314.9
Net Profit
Mgn %
-1.613.3-8.9-6.31.7-37-1.95.258
Debt to
Equity
-1.9-2.1-1.4-1.3-1.4-1.271.5-7.15.23.41.3
Working Cap
Days
16215912774867884978910657
Cash Conv.
Cycle
2-17-51-59-81-77-60-68-52-318

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Wanbury Ltd.

Standalone Consolidated
TTM EPS (₹) 14.4 12.3
TTM Sales (₹ Cr.) 629 630
BVPS (₹.) 30.7 19.2
Reserves (₹ Cr.) 72 32
P/BV 7.96 12.73
PE 17.02 19.86
From the Market
52 Week Low / High (₹) 155.00 / 330.00
All Time Low / High (₹) 0.85 / 330.00
Market Cap (₹ Cr.) 853
Equity (₹ Cr.) 34.9
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Wanbury:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *76.7476.7476.7471.0576.7476.7476.7476.7476.7471.73
* Pledged shares as % of Promoter's holding (%)

Valuation of Wanbury - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Wanbury

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales423434371391367393511500578600
Operating Expenses 391415439378389377479477506532
Manufacturing Costs31342522292731323838
Material Costs182197174196176221300303304294
Employee Cost 858887766764758187104
Other Costs 9297152841176473607795
Operating Profit 3219-6813-221632237268
Operating Profit Margin (%) 7.7%4.3%-18.3%3.4%-5.9%4.0%6.2%4.6%12.5%11.3%
Other Income 190771246551112
Interest 32363140332321212937
Depreciation 9101010101011121313
Exceptional Items 000083076-100
Profit Before Tax -762-32-2565-1281-103130
Tax 00-0-000-000-1
Profit After Tax -762-32-2564-1381-103031
PAT Margin (%) -1.7%14.3%-8.6%-6.3%17.5%-3.2%15.9%-2.1%5.3%5.1%
Adjusted EPS (₹)-3.526.7-13.5-10.525.8-5.024.9-3.29.39.3
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund -175-127-159-184-118-1311-92151
Share Capital 20232424252533333333
Reserves -195-151-183-208-143-156-31-42-1219
Minority Interest0000000000
Debt32221718220812488131396164
Long Term Debt23115499123100720082160
Short Term Debt9163838525161313144
Trade Payables8614083112121133179148163138
Others Liabilities 1551781631451461911521445753
Total Liabilities 386407268281274282345296338407

Fixed Assets

Gross Block326197199202203216227239248293
Accumulated Depreciation145102030394960728292
Net Fixed Assets 180186178172164167167167167201
CWIP 141010914112235
Investments 0000000000
Inventories35341319122550223638
Trade Receivables758529445134636989114
Cash Equivalents 79651712254613
Others Assets 75833131163338333736
Total Assets 386407268281274282345296338407

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 4343323044174120526
PBT -762-32-2565-1281-103130
Adjustment 48-374043-4133-44374248
Changes in Working Capital 218261221-33-7-68-51
Tax Paid -0-0-1-0-0-1-0-0-0-0
Cash Flow From Investing Activity -20-13-1-36481-9-17-51
Capex -21-15-3-5-8-41-9-14-48
Net Investments 0000000000
Others 22127112-11-3-3
Cash Flow From Financing Activity -28-27-33-27-108-17-29-321426
Net Proceeds from Shares 120000050000
Net Proceeds from Borrowing 0000000000
Interest Paid -23-16-7-11-11-7-15-17-35-35
Dividend Paid 0000000000
Others -17-11-27-15-97-11-63-154960
Net Cash Flow -53-2-0-0713-2121

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)N/AN/AN/AN/AN/AN/A0N/A502.7684.21
ROCE (%)N/AN/AN/AN/AN/AN/A206.26N/A61.8235.97
Asset Turnover Ratio1.111.121.171.511.341.421.641.591.841.62
PAT to CFO Conversion(x)N/A0.69N/AN/A0.69N/A0.51N/A0.170.84
Working Capital Days
Receivable Days73665332473935474961
Inventory Days29282214161726261822
Payable Days185209233181242210190197187187

Wanbury Ltd Stock News

Wanbury Ltd FAQs

The current trading price of Wanbury on 05-Dec-2025 16:59 is ₹238.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Wanbury stood at ₹853.5.
The latest P/E ratio of Wanbury as of 04-Dec-2025 is 17.02.
The latest P/B ratio of Wanbury as of 04-Dec-2025 is 7.96.
The 52-week high of Wanbury is ₹330.0 and the 52-week low is ₹155.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Wanbury is ₹628.7 ( Cr.) .

About Wanbury Ltd

Wanbury was incorporated in 1990 as a private limited company under the name of Pearl Distributors Private Limited. The name of the company was changed to 'Pearl Organics Private Limited on January 17, 1991 and the company was converted into a public limited company on August 6, 1991.

Wanbury is the fastest growing pharma company amongst top 100 companies in India as per ORG-IMS has strong presence in domestic branded formulations. Wanbury’s major thrust area also lies in Active Pharmaceutical Ingredient (API) and Contract Research and Manufacturing Services (CRAMS). It has a presence in Spain through its branded formulation business - Cantabria Pharma S. L acquired in 2006.

The company is having 3 API manufacturing facilities including 2 US FDA approved multi-product API facilities for regulated markets.

Product range of the company includes:

  • Coriminic table
  • Cpink table
  • Nock 2 tab
  • Senasof tab
  • Zevanuron
  • Rabiplus cap
  • Folinine
  • Cpink-s
  • Nuture
  • Adtrol 200mg

Milestones:

2008Wanbury opened an office in Zurich, Switzerland for its CRAMS business. Wanbury incorporated Wanbury Global FZE in Middle East for expanding its global business.Wanbury achieved consolidated turnover of Rs. 630 crore for 18 months period ended 30th September 2008. Rabiplus was awarded ‘Best Brand Launch’ by ORG-IMS as it did sales of Rs.13.8 crores in launch Year. Wanbury is the fastest growing company among top 100 companies in India as per ORG-IMS.

2007Doctor’s Organics Chemicals merged with Wanbury. Wanbury entered into a strategic association with Bravo Healthcare Wanbury incorporated Ningxia Wanbury Fine Chemicals Co to source raw materials from China. Wanbury approved as preferred Vendor by Pfizer (US) for Contract Research and Manufacturing Services (CRAMS). Cpink was awarded ‘Best Brand Launch’ by ORG-IMS as it did sales of Rs. 11 crores in launch year. Wanbury is the fastest growing company among top 100 companies in India as per ORG-IMS.

2006Wanbury achieved 100 crore turnover. Pharmaceutical Products of India (PPIL) merged with Wanbury pursuant to BIFR order. Wanbury acquired Cantabria Pharma S.L. with presence in ethical branded formulations in the Spanish market. Wanbury crossed 1000 employees mark. Wanbury became the world’s largest producer of Metformin with production of 4500 MT.

2005Wanbury acquired Doctor’s Organics and Chemicals, having a US FDA approved facility for manufacturing multi-product API’s.

2004Wander merged with Pearl Organics Limited and Pearl Organics renamed as Wanbury Wanbury set up its R & D center in Navi Mumbai for API. Wanbury started using SAP as a business transaction system.

2002Pearl Organics got US FDA approval for Patalganga plant.

1996Pearl Organics entered into a strategic alliance with Wyckoff Chemicals (US) to market its API in US.

1995Pearl Organics acquired plant of Brij Chemicals Pvt at Patalganga (Maharashtra).

1992Pearl Organics established its first plant in Tarapur for manufacturing API’s.

1991Pearl Distributors Pvt went public and was renamed as Pearl Organics.

1990Incorporated as Pearl Distributors Pvt

Achievements/ recognition:-

  • Wanbury ranks 47th as per ORG-IMS (Jan-2009) 
  • Cpink awarded “Best Brand Launch' by ORG IMS (06-07)  
  • Rabiplus awarded “Best Brand Launch' by ORG IMS (07-08) 
  • World's largest producer of Metformin
  • Fastest growing company amongst top 100 companies in the domestic market as per ORG IMS.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×